Melatonin alleviates postinfarction cardiac remodeling and dysfunction by inhibiting Mst1

Journal of Pineal Research

Volumn 62, Issue 1, 2017, Pages

  Hu, Jianqiang ^a,b   Zhang, Lei ^b   Yang, Yang ^c   Guo, Yanjie ^b   Fan, Yanhong ^b   Zhang, Mingming ^a,b   Man, Wanrong ^a,b   Gao, Erhe ^d   Hu, Wei ^c   Reiter, Russel J ^e   Wang, Haichang ^a,b   Sun, Dongdong ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

autophagy; mammalian Ste20 like kinase 1; melatonin; myocardial infarction; silent information regulator 1

Indexed keywords

ADENOSINE TRIPHOSPHATE; BAFILOMYCIN A1; BECLIN 1; LC3 II PROTEIN; MAMMALIAN STE20 LIKE KINASE 1; MELATONIN; MITOCHONDRIAL DNA; PHOSPHOTRANSFERASE; PROTEIN; PROTEIN P62; REACTIVE OXYGEN METABOLITE; SILENT INFORMATION REGULATOR 1; SILENT INFORMATION REGULATOR PROTEIN; UNCLASSIFIED DRUG; PROTEIN SERINE THREONINE KINASE; SIRT1 PROTEIN, MOUSE; SIRTUIN 1; STK4 PROTEIN, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CARDIAC DYSFUNCTION; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MECHANISM; ECHOCARDIOGRAPHY; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; MITOCHONDRIAL BIOGENESIS; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; STAINING; TUNEL ASSAY; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; IN SITU NICK-END LABELING; MELATONIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SIRTUIN 1; VENTRICULAR REMODELING;

EID: 84998673651     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12368     Document Type: Article

References (64)

1. Chen J, Hsieh AF, Dharmarajan K, et al. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998–2010. Circulation. 2013;128:2577–2584.
2. Tan DX, Manchester LC, Reiter RJ, et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta. 1999;1472:206–214.
3. Acuna-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71:2997–3025.
4. Illnerova H. Entrainment of mammalian circadian rhythms in melatonin production by light. Pineal Res Rev. 1988;61:174–218.
5. Menendez-Pelaez A, Reiter RJ. Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J Pineal Res. 1993;15:59–69.
6. Venegas C, Garcia JA, Escames G, et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52:217–227.
7. Rodella LF, Favero G, Foglio E, et al. Vascular endothelial cells and dysfunctions: role of melatonin. Front Biosci (Elite Ed). 2013;5:119–129.
8. Yeung HM, Hung MW, Lau CF, et al. Cardioprotective effects of melatonin against myocardial injuries induced by chronic intermittent hypoxia in rats. J Pineal Res. 2015;58:12–25.
9. Dominguez-Rodriguez A, Abreu-Gonzalez P, Piccolo R, et al. Melatonin is associated with reverse remodeling after cardiac resynchronization therapy in patients with heart failure and ventricular dyssynchrony. Int J Cardiol. 2016;221:359–363.
10. Yu L, Liang H, Lu Z, et al. Membrane receptor-dependent Notch1/Hes1 activation by melatonin protects against myocardial ischemia-reperfusion injury: in vivo and in vitro studies. J Pineal Res. 2015;59:420–433.
11. He B, Zhao Y, Xu L, et al. The nuclear melatonin receptor RORalpha is a novel endogenous defender against myocardial ischemia/reperfusion injury. J Pineal Res. 2016;60:313–326.
12. Nduhirabandi F, Lamont K, Albertyn Z, et al. Role of toll-like receptor 4 in melatonin-induced cardioprotection. J Pineal Res. 2016;60:39–47.
13. Simko F, Baka T, Paulis L, et al. Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review. J Pineal Res. 2016;61:127–137.
14. Pei H, Du J, Song X, et al. Melatonin prevents adverse myocardial infarction remodeling via Notch1/Mfn2 pathway. Free Radic Biol Med. 2016;97:408–417.
15. Kim CH, Kim KH, Yoo YM. Melatonin protects against apoptotic and autophagic cell death in C2C12 murine myoblast cells. J Pineal Res. 2011;50:241–249.
16. Fernandez A, Ordonez R, Reiter RJ, et al. Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis. J Pineal Res. 2015;59:292–307.
17. Kim C, Kim N, Joo H, et al. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol. 2005;46:200–210.
18. Gustafsson AB, Gottlieb RA. Autophagy in ischemic heart disease. Circ Res. 2009;104:150–158.
19. Terman A, Brunk UT. Autophagy in cardiac myocyte homeostasis, aging, and pathology. Cardiovasc Res. 2005;68:355–365.
20. Hu J, Man W, Shen M, et al. Luteolin alleviates post-infarction cardiac dysfunction by up-regulating autophagy through Mst1 inhibition. J Cell Mol Med. 2016;20:147–156.
21. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res. 2008;77:334–343.
22. Stein S, Lohmann C, Schafer N, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J. 2010;31:2301–2309.
23. Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res. 2010;48:9–19.
24. Hsu CP, Zhai P, Yamamoto T, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010;122:2170–2182.
25. Yu L, Liang H, Dong X, et al. Reduced silent information regulator 1 signaling exacerbates myocardial ischemia-reperfusion injury in type 2 diabetic rats and the protective effect of melatonin. J Pineal Res. 2015;59:376–390.
26. Yuan F, Xie Q, Wu J, et al. MST1 promotes apoptosis through regulating Sirt1-dependent p53 deacetylation. J Biol Chem. 2011;286:6940–6945.
27. Kaur H, Kumar A, Jaggi AS, et al. Pharmacologic investigations on the role of Sirt-1 in neuroprotective mechanism of postconditioning in mice. J Surg Res. 2015;197:191–200.
28. Agil A, El-Hammadi M, Jimenez-Aranda A, et al. Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. J Pineal Res. 2015;59:70–79.
29. Kireev R, Bitoun S, Cuesta S, et al. Melatonin treatment protects liver of Zucker rats after ischemia/reperfusion by diminishing oxidative stress and apoptosis. Eur J Pharmacol. 2013;701:185–193.
30. Yan W, Zhang H, Liu P, et al. Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1alpha signaling contributing to increased vulnerability in diabetic heart. Basic Res Cardiol. 2013;108:329.
31. Gao E, Lei YH, Shang X, et al. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res. 2010;107:1445–1453.
32. Sag CM, Kohler AC, Anderson ME, et al. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol. 2011;51:749–759.
33. Mei YA, Lee PP, Wei H, et al. Melatonin and its analogs potentiate the nifedipine-sensitive high-voltage-activated calcium current in the chick embryonic heart cells. J Pineal Res. 2001;30:13–21.
34. Xu M, Ashraf M. Melatonin protection against lethal myocyte injury induced by doxorubicin as reflected by effects on mitochondrial membrane potential. J Mol Cell Cardiol. 2002;34:75–79.
35. Sun D, Li S, Wu H, et al. Oncostatin M (OSM) protects against cardiac ischaemia/reperfusion injury in diabetic mice by regulating apoptosis, mitochondrial biogenesis and insulin sensitivity. J Cell Mol Med. 2015;19:1296–1307.
36. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005;26:1544–1550.
37. Vives-Bauza C, Starkov A, Garcia-Arumi E. Measurements of the antioxidant enzyme activities of superoxide dismutase, catalase, and glutathione peroxidase. Methods Cell Biol. 2007;80:379–393.
38. Jou MJ, Peng TI, Hsu LF, et al. Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2+)-mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res. 2010;48:20–38.
39. Da Silva CM, Macias-Garcia B, Miro-Moran A, et al. Melatonin reduces lipid peroxidation and apoptotic-like changes in stallion spermatozoa. J Pineal Res. 2011;51:172–179.
40. Zhang HM, Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res. 2014;57:131–146.
41. Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403–419.
42. Sahna E, Parlakpinar H, Ozer MK, et al. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res. 2003;35:257–261.
43. Ahmed HH, Mannaa F, Elmegeed GA, et al. Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity. Bioorg Med Chem. 2005;13:1847–1857.
44. Oz E, Erbas D, Surucu HS, et al. Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem. 2006;282:31–37.
45. Garcia JJ, Lopez-Pingarron L, Almeida-Souza P, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res. 2014;56:225–237.
46. Tengattini S, Reiter RJ, Tan DX, et al. Cardiovascular diseases: protective effects of melatonin. J Pineal Res. 2008;44:16–25.
47. Matsui Y, Takagi H, Qu X, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007;100:914–922.
48. Sishi BJ, Loos B, Van Rooyen J, et al. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol. 2013;85:124–134.
49. De Meyer GR, Martinet W. Autophagy in the cardiovascular system. Biochim Biophys Acta. 2009;1793:1485–1495.
50. Guo Y, Wang J, Wang Z, et al. Melatonin protects N2a against ischemia/reperfusion injury through autophagy enhancement. J Huazhong Univ Sci Technolog Med Sci. 2010;30:1–7.
51. Liu X, Chen Z, Chua CC, et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2002;283:H254–H263.
52. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011;51:1–16.
53. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res. 2013;54:245–257.
54. Sallinen P, Manttari S, Leskinen H, et al. Long-term postinfarction melatonin administration alters the expression of DHPR, RyR2, SERCA2, and MT2 and elevates the ANP level in the rat left ventricle. J Pineal Res. 2008;45:61–69.
55. Maejima Y, Kyoi S, Zhai P, et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med. 2013;19:1478–1488.
56. Fallahi E, O'driscoll NA, Matallanas D. The MST/Hippo pathway and cell death: a non-canonical affair. Genes (Basel). 2016;7. doi: 10.3390/genes7060028.
57. Nakamura M, Zhai P, Del Re DP, et al. Mst1-mediated phosphorylation of Bcl-xL is required for myocardial reperfusion injury. JCI Insight. 2016;1. pii: e86217.
58. Zhou Q, Li L, Zhao B, et al. The hippo pathway in heart development, regeneration, and diseases. Circ Res. 2015;116:1431–1447.
59. Marin-Garcia J, Goldenthal MJ, Moe GW. Mitochondrial pathology in cardiac failure. Cardiovasc Res. 2001;49:17–26.
60. Gottlieb RA, Gustafsson AB. Mitochondrial turnover in the heart. Biochim Biophys Acta. 2011;1813:1295–1301.
61. Tokarska-Schlattner M, Zaugg M, Zuppinger C, et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006;41:389–405.
62. Tan DX, Manchester LC, Liu X, et al. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res. 2013;54:127–138.
63. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342.
64. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–1122.